Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited.

BACKGROUND The Will Rogers phenomenon occurs when newer technology allows for more sensitive detection of tumor spread, resulting in stage migration and an apparent improvement in patient survival. We investigated whether use of highly sensitive positron emission tomography (PET) scanning in non-small cell lung cancer has had this effect. METHODS We performed a retrospective analysis involving 12,395 patients with non-small cell lung cancer in the pre-PET (1994-1998) and PET (1999-2004) periods. Interperiod differences in staging procedures, clinical variables, and patient survival were evaluated. RESULTS There was a 5.4% decline in the number of patients with stage III disease and an 8.4% increase in the number of patients with stage IV disease in the PET period, corresponding with an increase in PET use from 6.3% to 20.1% (P < .001). The PET period predicted better survival with a hazard ratio (HR) of 0.95 (95% confidence interval [CI], 0.91-0.99) (P = .02). Use of PET was independently associated with better survival in patients with stage III (HR, 0.77; 95% CI, 0.69-0.85) and stage IV (HR, 0.64; 95% CI, 0.58-0.70) disease, but not those with stage I or II disease. CONCLUSION These data support the notion that stage migration is responsible at least in part for an apparent improvement in survival for patients with stage III and IV non-small cell lung cancer in the PET scan era.

[1]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[2]  S. Berlangieri,et al.  Prevalence of occult metastatic disease in patients undergoing 18F‐FDG PET for primary diagnosis or staging of lung carcinoma and solitary pulmonary nodules , 2007, Internal medicine journal.

[3]  T. Wasser,et al.  Evidence for the will rogers phenomenon in migration of employees to managed care plans , 1999, Journal of General Internal Medicine.

[4]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[5]  B. Cheson,et al.  Positron-emission tomography and assessment of cancer therapy. , 2006, The New England journal of medicine.

[6]  J. Crowley,et al.  Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Xin Li,et al.  TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Socinski Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer , 2004, Clinical Cancer Research.

[9]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  W. Wright,et al.  Socioeconomic status and breast cancer incidence in California for different race/ethnic groups , 2001, Cancer Causes & Control.

[11]  B. Yalcin,et al.  Multidisciplinary management of lung cancer. , 2004, The New England journal of medicine.

[12]  J. Ornato,et al.  Impact of the troponin standard on the prevalence of acute myocardial infarction. , 2003, American heart journal.

[13]  P. Bunn Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[15]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[16]  J. Crowley,et al.  Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Lori S. Parsons Reducing Bias in a Propensity Score Matched-Pair Sample Using Greedy Matching Techniques , 2001 .

[18]  H. Groen,et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. , 2000, The New England journal of medicine.

[19]  R. D'Agostino Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[20]  A R Feinstein,et al.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. , 1985, The New England journal of medicine.

[21]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[22]  P. Trott,et al.  International Classification of Diseases for Oncology , 1977 .

[23]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[24]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[25]  D.,et al.  Regression Models and Life-Tables , 2022 .